Everything below concerns Heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-14. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
== Young adults == By far, the most common cause of severe hypoglycemia in this age range is insulin injected for type 1 diabetes. Circumstances should provide clues fairly quickly for the new diseases causing severe hypoglycemia. All of the congenital metabolic defects, congenital forms of hyperinsulinism, and congenital hypopituitarism are likely to have already been diagnosed or are unlikely to start causing new hypoglycemia at this age. Body mass is large enough to make starvation hypoglycemia and idiopathic ketotic hypoglycemia quite uncommon. Recurrent mild hypoglycemia may fit a reactive hypoglycemia pattern, but this is also the peak age for idiopathic postprandial syndrome, and recurrent "spells" in this age group can be traced to orthostatic hypotension or hyperventilation as often as demonstrable hypoglycemia.
== Career == Bhatia began her academic career in 1998, joining the bioengineering faculty at the University of California, San Diego (UCSD). As an assistant professor, she was awarded a five-year Packard Fellowship for Science and Engineering from the David and Lucile Packard Foundation in 1999. She was recognized with a "Teacher of the Year" award at the Jacobs School of Engineering in 2001, and was named an "Innovator under 35" by MIT Technology Review in 2003. Bhatia co-authored the first undergraduate textbook on tissue engineering, Tissue engineering (2004), written for senior-level and first-year graduate courses with Bernhard Palsson. She was a co-editor of Microdevices in Biology and Medicine (2009) and Biosensing: International Research and Development (2005). In 2005, she joined the MIT faculty in the Division of Health Sciences & Technology and the Department of Electrical Engineering and Computer Science. The Scientist named her a "Scientist to Watch" in 2006, and she became a Howard Hughes Medical Institute Investigator in 2008. Since 2013, Bhatia has expanded her affiliations within MIT and Harvard, including the Ludwig Center for Molecular Oncology (2013), the Broad Institute of MIT and Harvard (2014), the MIT Center for Neurobiological Engineering (2016), the Wyss Institute for Biologically Inspired Engineering (2018), and the Martin Trust Center for MIT Entrepreneurship (2022). Bhatia currently directs the Laboratory for Multiscale Regenerative Technologies and the Marble Center for Cancer Nanomedicine at MIT.
== Banned anabolic agents == Banned anabolic agents are, for the purpose of WADA, either anabolic steroids, which activate testosterone and epitestosterone receptors, thereby improving muscle strength and endurance, or "other anabolic agents". Andro, DHEA, stanozolol, testosterone, and nandrolone, or derivates (see below) are banned anabolic steroids. Other banned anabolic agents include clenbuterol, tibolone, zeranol, zilpaterol, and selective androgen receptor modulators. While a few of the banned drugs are endogenous, that is they are normally produced in the human body, most of the banned drug are exogenous drugs chemically produced. These types of drugs were used extensively in Major League Baseball in the 1990s and early 2000s.
Sources: en.wikipedia.org
These non-peptide inhibitors can be more stable than inhibitors containing peptide bonds, because they will not be substrates for peptidases and are less likely to be degraded. In drug design it is important to consider the concentrations of substrates to which the target enzymes are exposed. For example, some protein kinase inhibitors have chemical structures that are similar to ATP, one of the substrates of these enzymes. However, drugs that are simple competitive inhibitors will have to compete with the high concentrations of ATP in the cell. Protein kinases can also be inhibited by competition at the binding sites where the kinases interact with their substrate proteins, and most proteins are present inside cells at concentrations much lower than the concentration of ATP. As a consequence, if two protein kinase inhibitors both bind in the active site with similar affinity, but only one has to compete with ATP, then the competitive inhibitor at the protein-binding site will inhibit the enzyme more effectively.
Smoking is the cause of more than 7 million deaths per year, making it the most common cause of preventable early death. One study found that male and female smokers lose an average of 13 and 15 years of life, respectively, while another measured a loss of life of 7 years. Each cigarette is estimated to shorten life by an average of 11 minutes, though this may vary slightly depending on the contents and brand. More recently, it has been reported to be 20 minutes. At least half of all lifelong smokers die early as a result of smoking. Smokers are three times more likely to die before the age of 70 than non-smokers. In the United States, cigarette smoking and exposure to tobacco smoke account for roughly one in five, or at least 443,000 premature deaths annually. To put this into context, ABC's Peter Jennings (who would later die at 67 from lung cancer caused by life-long smoking) famously reported that in the US alone, smoking tobacco kills the equivalent of three jumbo jets full of people crashing every day, with no survivors. On a worldwide basis, this equates to a single jumbo jet every hour. A 2015 study found that about 17% of mortality due to cigarette smoking in the United States is due to diseases outside of those commonly linked with smoking. Official estimates may therefore be significantly underestimating the number of deaths currently being attributed to smoking. It is estimated that there are between 1 and 1.4 deaths per million cigarettes smoked. Cigarette factories are the most deadly factories in the history of the world.
=== 15 April === Poland and Hungary banned imports of grain and some other food from Ukraine "to protect the local agricultural sector", due to Ukrainian supplies lowering the price of food. The bans were criticized by the Ukrainian Ministry of Agrarian Policy as contradicting bilateral agreements on exports, while the European Commission said that "unilateral actions are not acceptable". Jarosław Kaczyński, the leader of the Polish Law and Justice party, said that Poland will continue supporting Ukraine and that it was ready to start talks to settle the issue.
Sources: en.wikipedia.org
This scenario usually occurs at very low solidification velocities (< 1 μm s−1) or with extremely fine particles because they can move by Brownian motion away from the front. The resultant structure contains no macroporosity. If one were to increase the solidification speed, the size of the particles or solid loading moderately, the particles begin to interact in a meaningful way with the approaching ice front. The result is typically a lamellar or cellular templated structure whose exact morphology depends on the particular conditions of the system. It is this type of solidification that is targeted for porous materials made by freeze-casting. The third possibility for a freeze-cast structure occurs when particles are given insufficient time to segregate from the suspension, resulting in complete encapsulation of the particles within the ice front. This occurs when the freezing rates are rapid, particle size becomes sufficiently large, or when the solids loading is high enough to hinder particle motion. To ensure templating, the particles must be ejected from the oncoming front. Energetically speaking, this will occur if there is an overall increase in free energy if the particle were to be engulfed (Δσ > 0).
is the number of theoretical plates (also called the "plate count"), H is the total bed height and HETP is the height equivalent to a theoretical plate. The material in packed beds can either be random dumped packing (1-3" wide) such as Raschig rings or structured sheet metal. Liquids tend to wet the surface of the packing and the vapors contact the wetted surface, where mass transfer occurs.
=== Neurohormone === GnRH is considered a neurohormone, a hormone produced in a specific neural cell and released at its neural terminal. A key area for production of GnRH is the preoptic area of the hypothalamus, which contains most of the GnRH-secreting neurons. GnRH neurons originate in the nose and migrate into the brain, where they are scattered throughout the medial septum and hypothalamus and connected by very long >1-millimeter-long dendrites. These bundle together so they receive shared synaptic input, a process that allows them to synchronize their GnRH release. The GnRH neurons are regulated by many different afferent neurons, using several different transmitters (including norepinephrine, GABA, glutamate). For instance, dopamine appears to stimulate LH release (through GnRH) in estrogen-progesterone-primed females; dopamine may inhibit LH release in ovariectomized females. Kisspeptin appears to be an important regulator of GnRH release. GnRH release can also be regulated by estrogen. It has been reported that there are kisspeptin-producing neurons that also express estrogen receptor alpha.
The industry has experienced an increase in private equity investment and this has led to the consolidation of choices in the CDMO industry as many larger CDMOs have been formed. Many of those are active at aiming to be larger scale suppliers in the CDMO environment but the number of attractive acquisitions are limited. One could argue that this has had both positive and negative effects on the industry. Larger pharma companies like the idea of a larger CDMO while smaller pharma companies tend to see it more difficult to get the kind of service they expect.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.